The Wistar-Kyoto (WKY) rat strain demonstrates endogenous hormonal and behavioral abnormalities that emulate many of those found in symptom-presenting depressive patients. Evidence suggests that the WKY strain may harbor heterogeneity not found in other inbred strains, including greater behavioral and genetic variability. We took advantage of this variability and selectively bred WKY for 'depressive' behavior using immobility in the forced swim test (FST) as a functional selector. Successive generations of selective breeding resulted in rats that exhibited the extremes of immobility in the FST: 'WKY most immobile' (WMI) and 'WKY least immobile' (WLI). Male WMI rats also showed significantly decreased activity in the open field test (OFT). Plasma corticosterone (CORT) response to restraint stress was significantly lower and less variable in WMI compared to WLI males. Subacute treatment of males with several classes of antidepressant had different effects on FST behavior in the two substrains. Both desipramine (10 mg/kg body weight), a tricyclic antidepressant, and phenelzine (7.5 mg/kg), a monoamine oxidase inhibitor, significantly and drastically decreased FST immobility in WMI. In contrast, WLI showed a limited response to these antidepressants. Neither substrain responded to fluoxetine (10 mg/kg), a selective serotonin reuptake inhibitor. These data show that selective breeding of WKY rats has resulted in two substrains with reduced variability and differing responsiveness to antidepressants, which represent a novel means to dissect the molecular mechanisms underlying depressive behavior. Molecular Psychiatry (2003) 1 Although WKY serves as the control strain for studies on hypertension, its behavior is not 'normal'. Compared to many other strains, WKY demonstrates hormonal, behavioral, and physiological measures that emulate those found in symptompresenting depressive patients.
The Wistar-Kyoto (WKY) rat strain has been proposed as an animal model of endogenous depression. Initially developed as the normotensive control strain for the spontaneously hypertensive rat, WKY was bred from the Wistar (Wi) strain in 1963 by Okamoto and Aoki. 1 Although WKY serves as the control strain for studies on hypertension, its behavior is not 'normal'. Compared to many other strains, WKY demonstrates hormonal, behavioral, and physiological measures that emulate those found in symptompresenting depressive patients.
WKY rats are hyper-reactive to stress and show dysregulation of the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-thyroid (HPT) axes. We previously showed that compared to Wi rats, basal plasma adrenocorticotropic hormone (ACTH) and corticosterone (CORT) levels of WKY rats remain significantly higher for several hours after the diurnal peak. 2 They also display increased steadystate levels of anterior pituitary pro-opiomelanocortin (POMC) mRNA and exaggerated plasma ACTH responses to acute and chronic stress compared to other rat strains. 3, 4 A number of laboratories have found that WKY rats exhibit depressive-like behavior in a wide range of accepted behavioral paradigms. Increased immobility in the forced swim test (FST), considered as a measure of depressive-like behavior, [5] [6] [7] has been found in many studies. [8] [9] [10] [11] [12] Among other assessments of depressive or anxious behavior, WKY rats also show decreased activity in the open field test (OFT), a measure of anxiety/fear, 9, 13 and in the defensive burying test (DB), a potential measure of passive coping. 9 Several studies have found that WKY rats show reduced responsiveness to tricyclic antidepressants (TCA) compared to Brown Norway, Lewis, Fisher 344 (F344), 11 and Sprague Dawley (SD) 14 rats, while others have reported increased responsiveness to TCA antidepressants. 15 Fluoxetine (selective serotonin reuptake inhibitor, SSRI) has variable effects on FST behavior in several strains, [15] [16] [17] [18] although WKY appears to be particularly resistant 15 . While the WKY strain has been shown to be a reliable animal model of endogenous depression, we and others have found greater phenotypic and genotypic variability among WKY rats compared to other inbred strains. Variability has been found in several behavioral and physiological measures 19, 20 as well as genotypic heterogeneity between WKY rats obtained from different sources and within individual colonies. [21] [22] [23] Additionally, the responsiveness of WKY rats to antidepressants shows a wide range not found in other strains.
We hypothesized that the variability in behavior and the genetic heterogeneity of the WKY strain are linked, and that selective breeding based on immobility in the FST would result in two distinct substrains differing in FST immobility and in the genetic substrate associated with this behavioral phenotype. Here we characterize early generations of the two resulting substrains, 'WKY most immobile' (WMI) and 'WKY least immobile' (WLI), in behavioral measures and determine their responsiveness to several classes of antidepressant.
Materials and methods

Animals
Adult male SD, F344, Wi, WKY, and female WKY rats were purchased from Harlan (Indianapolis, IN, USA) and all animals were tested in the FST. Animals were housed in a controlled temperature vivarium with a 12 : 12 light cycle, lights on at 07.00 h, with standard laboratory rat chow and water ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee of Northwestern University.
Parental animals were selected from WKY adults. Males and females with the highest immobility and lowest climbing scores in the FST were mated, producing the WMI line. Males and females with the lowest immobility and highest climbing scores were mated, producing the WLI line. Three pairs for each line were mated. Litters were weaned at 4 weeks of age and group housed by litter and sex throughout testing.
Two to four breeding pairs were selected for WMI and WLI lines in subsequent generations. Animals showing the most extreme FST behavior within each line were selected for breeding, specifically avoiding sibling mating until the F5 generation, when sibling mating was started. All WMI and WLI animals were tested in the FST at 10 weeks of age. Blood samples were collected from F3 generation animals to measure baseline plasma thyroid hormone (T3) and CORT levels at 11 weeks of age. These animals were tested in the OFT at 12 weeks, and in the FST with subacute antidepressant treatment at 14 weeks of age. Blood samples were collected from F4 generation animals to measure stress plasma CORT level at 12 weeks of age. These animals were tested in the DB at 11 weeks, and in the FST with subacute antidepressant at 14 weeks of age. (Ages given are 74 days.)
Behavioral tests
For all behavioral tests, rats were brought to the testing area 2 h before the start of testing. Tests were videotaped and later scored by a trained observer. Each behavioral measure in every test was analyzed by a two-way ANOVA (sex and substrain). Behavioral measures in the FST with subacute antidepressant treatments were analyzed by a two-way ANOVA (substrain and treatment) with repeated measures (testing with and without antidepressant treatment). Post hoc analyses were conducted by two-tailed t-test when significance warranted the analysis.
Forced swim test
The FST procedure was adapted from Porsolt et al 6 and Detke et al 24 as previously described. 25 At testing, rats were placed individually in a glass tank (30 cm Â 45 cm) of water (251C) for 15 min. After 24 h, rats were once again placed in the tank for a 5 min period. After swimming, animals were placed in warmed holding cages for at least 30 min before being returned to their home cages. All testing took place between 11.00 and 15.00 h. The 5 min test sessions were sampled every 5 s and scored for floating, swimming, climbing, and diving (scoring system of Detke et al 24 ). Our scoring was quite strict: any limb movement was scored as swimming and animals had to raise themselves in the water to be scored as climbing.
Open field test
Rats were placed individually into the center of the open field for 15 min. The arena was circular with 81 cm diameter and 30 cm wall; the floor was marked with three concentric circles, the second circle divided into six sections, the third divided into 12 sections. The arena was cleaned with a 1.25% acetic acid solution between animals. Tests were scored for number of lines crossed, rears, and time spent in the center. An animal had to move more than half of its body across a line or into a section to be scored as crossing a line or entering an area and both paws had to be aloft to be scored as rearing.
Defensive burying test
The test was administered in a 40 cm square 60 cm high Plexiglas box with bedding (7 cm deep) and a prod (9 cm long) inserted and mounted to the side of the box 1 cm above the surface of the bedding. For 3 days before the test session, animals were habituated to the test area with their cage mates for 15 min. On the day of the test, the electrified prod was added; when touched, the probe circuit closed and the rat received a shock. Females received a 5.0 mA shock and males a 5.5 mA shock. The test session continued for 15 min after the initial shock. Tests were scored for time to initial shock, latency to bury, duration of burying, grooming, rearing, and number of shocks.
Subacute antidepressant treatment in FST Animals were first tested in FST at 10 weeks of age and subsequently tested with subacute antidepressant treatment at 14 weeks of age. On the first day of the test, animals were weighed when brought to the testing area. The protocol was as described above for the FST with the addition of antidepressant treatment between the two tests. After the 15 min first swim, the animals received subcutaneous injections of either desipramine (10 mg/kg), phenelzine (7.5 mg/kg), fluoxetine (10 mg/kg), or water (1 ml/kg) at 23.5, 4, and 1 h prior to the 5 min test swim on the second day. The desipramine and fluoxetine doses were chosen based on Lopez-Rubalcava et al. 15 Phenelzine doses were based on a pilot study where doses of 5.0 or 7.5 mg/kg were given with a subacute treatment paradigm in FST to WMI and WLI rats (group n ¼ 3) and behavior was assessed. A vehicle control (water) was used to test for possible effects of repeated FST on FST behavioral measures.
Blood collection
Baseline blood samples were collected between 22.00 and 23.00 h and stress samples were taken between 10.00 and 11.00 h. Each animal was quickly removed from its cage and restrained in a ventilated clear acrylic tube with an adjustable rear wall. For basal hormone levels, tails were immediately nicked and blood collected in a 1.5 ml Eppendorf tube with 12 ml 0.5 M EDTA. Collection was stopped within 3 min of initial contact with the animal and 2 min of tail nick. Stress blood samples were taken in the same manner, after a 10 min restraint.
Radioimmunoassay
Assays were performed in triplicate and all samples were assayed in a single assay. Plasma T3 was measured using ImmunoChem-coated tubes from ICN Pharmaceuticals, Inc. (Costa Mesa, CA, USA), using 100 ml of unextracted plasma and 125 I-labeled T3 as tracer (provided) at 371C for 1 h. The assay sensitivity was 4.3 ng/dl. The intra-assay coefficient of variation was 1.4%.
Plasma CORT was measured as previously described. 3 Briefly, 2 ml of plasma was incubated overnight with the primary CORT antibody raised against CORT 3-carboxymethyloxime-bovine serum albumin and 125 I-labeled CORT conjugate as the tracer (ICN Pharmaceuticals, Inc., Costa Mesa, CA, USA). The assay sensitivity was 8.4 pg/tube. For baseline CORT measurements, the intra-assay coefficient of variation was 2.2%; for stress CORT measurements it was 3.6%.
Genotyping
Genotyping was performed using 39 simple sequence length polymorphism (SSLP) markers. Of these markers, 31 were among those found by Deschepper et al 23 (out of 216 tested) to be polymorphic between WKY rats from different breeding sources or to show heterozygosity within these source populations. An additional eight SSLP markers were used that had been found to be heterozygous in Harlan WKY in our lab. The first round of genotyping was carried out on genomic DNA isolated from seven male parental WKY. A second round of genotyping was carried out on 10 female and 10 male WKY, with the six primer pairs that showed heterozygosity in the first round.
Briefly, genomic DNA was isolated from spleen, tail, or cerebellum by digestion with proteinase K, phenol extraction, phenol/chloroform extraction, and 70% ethanol wash. Each sample (12.5 ng) was placed in the wells of a 96-or 192-well reaction plate and dried. Marker forward primers (Integrated DNA Technology, Inc., Coralville, IA, USA) were radiolabeled with 32 P-gamma dATP (Amersham Biosciences, Piscataway, NJ, USA) by incubation with T4 kinase (10 U/ml, Gibco Life Technologies, Inc., Gaithersburg, MD, USA). This radio-labeled forward primer was combined with dNTPs (0.2 mM, Roche Molecular Systems, Inc., Alameda, CA, USA), reverse marker primer (Integrated DNA Technology, Inc.), 50 mM KCl, 10 mM Tris-HCl (pH 8.3), MgCl 2 (2.1 mM), bovine serum albumin (1 mg/ml), and AmpliTaq Gold (0.125 U per reaction, Perkin-Elmer Corp., Foster City, CA, USA); 5.0 ml of mix was added to each plate well. DNA was amplified by PCR in a PTC-200 cycler (MJ Research, Inc., Waltham, MA, USA).
Products from PCR were combined with 5.0 ml stop/ loading buffer, denatured, and electrophoresed on an 8% acrylamide gel in an EC160 vertical DNA sequencing gel box (Fisher Scientific, Hanover Park, IL, USA) at 2000 V/66 mA/90 W for approximately 2 h. Gels were then exposed to radiographic film (Hyperfilm MP, Amersham Pharmacia Biotech, Piscataway, NJ, USA) at À801C for at least 24 h. Films were developed and scored manually.
Results
FST immobility (time floating) in adult F344 (inbred), SD (outbred), Wi (outbred), and WKY (theoretically inbred) males is shown in Figure 1 . WKY rats showed not only significantly greater immobility, but also greater variability of immobility than all of the other strains (F[3, 45] ¼ 13.1, po0.01, WKY vs the other three strains, po0.01).
To determine the extent of genetic heterogeneity within our WKY stock (Harlan WKY/NHsd), rats were genotyped using 39 SSLP markers. In total, 31 markers were among those found by Deschepper et al (out of 216 tested) to be polymorphic between WKY rats from Charles River Laboratories and NIH or to show heterozygosity within these source populations; 23 eight markers were used that had been found to be heterozygous in Harlan WKY in our lab. Of these, seven were found to be polymorphic within our WKY stock. Table 1 shows the lengths and frequencies of these. For comparison, lengths of Charles River and NIH SSLP markers are included as described by Deschepper et al. 23 Marker lengths for WKY/NHsd rats displayed a mix of those of Charles River and NIH WKY rats. The frequency of heterozygosities ranged from 3 to 7 out of 26 animals (12-27%).
Selective breeding using FST behavior as a functional selector resulted in the maintenance of significant differences in FST immobility between WMI and WLI lines after the first generation. The FST immobility of the WKY pool was 8.373.5 for females and 13.274.3 for males; the immobility of selected parental animals was WMI female 14.072.8, WMI male 18.570.7, WLI female 5.273.3, and WLI male 1.0 (means7SD). When averaged across generations, including the WKY pool from which the parental generation was selected and the first seven generations of selectively bred animals (female, n ¼ 210; male, n ¼ 250; WKY, n ¼ 22; WMI, n ¼ 218; WLI, n ¼ 220), the differences in immobility between parental pool and both substrains were highly significant (F[2, 459] ¼ 76.8, po0.01; WMI/WLI, po0.01, WKY/WMI, po0.01, WKY/WLI, po0.01). However, it is important to note that the F1 generation showed no significant difference from the parental pool WKY; the significant differences appeared in the F2 generation. Figure 2 shows (Figure 3) . Total lines crossed, a measure of activity, showed significant differences between substrains (F[1, 68] ¼ 13.1, Figure 2 FST immobility of WMI and WLI substrains. FST immobility was measured as described in Figure 1 . We recently reported substantial alterations in plasma T3 levels throughout the day and increased basal plasma CORT levels around 22.30 h in WKY compared to Wi rats. 2 Therefore, we measured these plasma hormone levels in WMI and WLI rats ( Table 2) . No significant differences were found between male WMI and WLI basal plasma T3 and CORT levels measured at 22.30 h. However, plasma CORT levels in response to restraint stress were significantly greater and more variable in WLI than WMI (F[1, 24] ¼ 4.39, po0.05).
The response of these substrains to antidepressants was tested using three different classes of antidepressant in a subacute treatment paradigm, in which antidepressants were administered in the 24 h period between tests (Figure 4) . The vehicle control group showed no significant change in behavior between the first and second FST 4 weeks later. This allowed us to use an animal as its own control; that is, we compared the behavior of the naïve animal in the first FST with the behavior of the same animal after antidepressant treatment in the second FST. In Post hoc analysis confirmed that the substrains had very different responses to the different classes of antidepressant. WMI males responded significantly to desipramine (a tricyclic antidepressant (TCA), 10 mg/ kg) treatment with a large decrease (74.4%) in FST floating (WMI/DMI, po0.01) and increase in climbing (WMI/DMI, po0.01). WLI males showed a nonsignificant decrease (33.3%) in floating and only a slight significant increase in climbing (WLI/DMI, po0.05). Phenelzine (a monoamine oxidase inhibitor (MAOI), 7.5 mg/kg) significantly and greatly reduced (55.5%) immobility of WMI males (WMI/PHZ, po0.01), with Baseline plasma samples were collected between 22.00 and 23.00 h from F3 generation WMI and WLI males at 11 weeks of age. Stress plasma samples were collected between 10.00 and 11.00 h from F4 generation WMI and WLI males at 12 weeks of age. WMI: baseline T3 n=17, CORT n=20, stress CORT n=12, WLI: baseline T3 n=9, CORT n=8, stress CORT n=12. Values are means7SEM. * p>0.05 WMI vs WLI.
a smaller effect (39.3%) on WLI males (WLI/PHZ, po0.05). However, phenelzine had no effect on climbing in either substrain. Fluoxetine (a selective serotonin reuptake inhibitor (SSRI), 10 mg/kg) resulted in no significant change in immobility or climbing in either substrain.
To determine the extent of genetic heterogeneity within our WMI and WLI substrains, the eight F7 generation animals selected to breed and 40 of the resulting F8 generation offspring were genotyped using the seven SSLP markers previously found to be heterozygous in WKY/NHsd. Of these, only one was found to be polymorphic in the F7 and F8 generation. (Table 3 shows F8 generation data.)
Discussion
Breeding animals from a similar genetic background by functional selection has produced two substrains of the WKY rat with consistently differing behavior in the FST. Both substrains have reduced behavioral and genetic variability. Additionally, WMI shows hyperresponsiveness to two classes of antidepressant.
While the WKY strain has been proposed as a good model of endogenous depression, many studies have detected phenotypic and genotypic variability of unknown origin. We have shown WKY rats obtained from Harlan (WKY/NHsd) display behavioral variability three times greater than that of other inbred or outbred strains. Although these studies kept the environment as stable as possible, the WKY strain is hyper-reactive to stress and may react to subtle environmental stimuli more than other strains. While this environmental contribution to the behavioral heterogeneity cannot be excluded, the genetic heterogeneity of the WKY strain may well be a major component of its behavioral variability. The behavioral and genotypic heterogeneity of WKY/NHsd is atypical of an inbred line. It is unlikely that this heterogeneity is because of a lack of complete inbreeding at the time of distribution by NIH. If this were the source, variability would exist only between different vendor populations (NIH, Charles River Laboratories, Inc., Harlan). 19, 20 However, genetic variability also exists within single vendor populations. 21, 23 In the case of WKY/NHsd, this variability exists despite many generations of inbreeding. It is possible that heterogeneity in the strain is because of the development of new mutations. 26, 27 Including all types of mutations (base pair substitutions, additions, Simple sequence length polymorphisms expressed in base pairs. N/A=not applicable.
and deletions, and larger or more complex changes) the mutation rates estimated from specific loci in mouse is 0.9 and in humans is 1.6 mutations per genome per sexual generation. 28 Given that the WKY strain has been maintained at Harlan for over 67 generations, this would allow time for a great number of mutations to accumulate, especially if the strain is particularly susceptible.
The WMI and WLI substrains have maintained the extremes of FST behavior with less variability for seven generations. These substrains also differed in activity, with WMI males showing hypoactivity in the OFT. It is unlikely that this hypoactivity indicates increased fear/anxiety 9,29 since there were no significant differences between WMI and WLI rats in the DB, which has several measures specific for anxiety. 30, 31 Thus, hypoactivity of WMI males in the OFT is in accord with their depressive-like behavior in the FST. Further, WLI males had a higher plasma CORT response to restraint stress than WMI males, in agreement with our previous findings that 'normal' F344 males have a higher plasma CORT response to the same restraint stress than 'depressed' WKY males. 25 Although elevated HPA activity has been thought to be associated with depression, recent reports have found no such correlation in animal models. 25, 32 Further, it has been reported that depressed patient subtypes can show either increased or decreased HPA activity. 33 Several other rat lines have been selectively bred based on behavioral paradigms, usually starting with outbred populations. SD rats have been selectively bred for vulnerability and resistance to develop learned helplessness (LH). 34, 35 This resulted in a line that readily acquires LH, 'congenital LH' (cLH), and the LH-resistant line, 'congenital non-LH' (cNLH). The cLH rats do not respond to antidepressants, 36 show altered HPA axis response to stress 37, 38 and may model aspects of post-traumatic stress disorder. 39 Another group bred SD based on activity in a 1-day FST and has produced low and high activity animals (SwLo and SwHi). 40, 41 Swimming in the SwLo animals increases in response to drugs that affect dopamine neurotransmission. 42 Dopamine function appears to be altered in these animals, 42 ,43 making them useful for studying depressive symptoms related to dopamine function such as anhedonia.
The key difference between the selectively bred animal models of depressive behavior described, and the WMI and WLI substrains is that the WKY substrains were derived from a theoretically inbred strain of an accepted animal model of depression. One advantage is that the behavior and physiology of the WKY strain are well characterized. Further, the WMI and WLI substrains are genetically almost identical, yet FST behavior and antidepressant response segregated in these lines. All but one of the seven genotypic SSLP marker polymorphisms detected in the WKY/NHsd were no longer detected in either WMI or WLI by the F8 generation. While none of these polymorphisms segregated with behavior, any remaining genetic differences between the WMI and WLI lines are likely to be associated with these segregated traits. Genetic characterization of WMI and WLI substrains could aid in identifying chromosomal locations and genes associated with FST behavior and antidepressant response. However, the same genetic similarity of these two substrains could be a disadvantage, as it does not allow the application of classical genetic tools.
Several previous studies have concluded that the WKY strain might be resistant to antidepressant treatment. Lahmame et al found reduced responsiveness to subacute 11 and chronic 14 antidepressant treatment in WKY rats compared to several other strains. Immobility decreased and climbing increased in the FST of WKY rats only at high doses (25 mg/kg) of desipramine. Lopez-Rubalcava and Lucki 15 administered antidepressants in the same subacute paradigm and found a marked response to desipramine, starting at only 5 mg/kg, but no consistent response to fluoxetine (SSRI), even at 40 mg/kg. Perhaps the explanation of these results is that commercially available WKY rats harbor a wide range of responsiveness to antidepressants and different vendor populations contain different proportions of the animals. This would not be surprising considering the behavioral and genetic variability found in WKY.
The differing response of the two substrains to subacute antidepressant treatments is an unexpected confirmation of subpopulation differences. Subacute treatment with desipramine and phenelzine greatly reduced immobility in WMI rats, but only phenelzine had any significant effect on immobility of WLI rats. WLI exhibit low immobility and changes in response to desipramine treatment in the FST similar to that of control strains, such as F344, Brown Norway, and SD. 11, 14, 15 The responsiveness of WMI to these antidepressants is more than two times greater when compared to WLI or to unselected WKY 15 (our own unpublished data). Neither substrain responded to fluoxetine, confirming previous findings in WKY, 15 SD, 16 and Wi 17,18 rats. From a commercially available WKY strain that exhibits behavioral and genotypic variability, we successfully established two substrains using FST behavior as a functional selector for breeding. These substrains, WMI and WLI, in addition to differing in FST and OFT behavior, show differential sensitivity to the TCA desipramine and the MAOI phenelzine. Further study will use these unique substrains to examine the gene expression profile and genetic architecture of depressive behavior and antidepressant responsiveness. Results of these analyses may help to elucidate the genetic mechanisms underlying human depressive disorders.
